What question did this study set out to answer?

This case report aims to demonstrate the efficacy of Ravulizumab in treating a pediatric patient with treatment-resistant IgA nephropathy.

May 31, 2026Kidney International Case ReportsOpen Access

Ravulizumab in Treatment Resistant Paediatric IgA Nephropathy – a Case Report

View Full Paper

Ask AI

Bookmark

This case report aims to demonstrate the efficacy of Ravulizumab in treating a pediatric patient with treatment-resistant IgA nephropathy.
Case report of a 7-year-old boy diagnosed with IgA nephropathy after kidney biopsy.
Patient received various treatments including steroids, lisinopril, MMF, and tacrolimus without significant improvement in proteinuria.
Compassionate use of Ravulizumab was initiated when other treatments failed.
One month after starting Ravulizumab, the patient's urine ACR significantly decreased to 9-11 mg/mmol.
The patient maintained a sustained reduction in proteinuria while on Ravulizumab, tacrolimus, and lisinopril.
Repeat biopsy showed persistent active disease despite previous treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Case report reveals successful treatment of proteinuria in a child with IgA nephropathy using Ravulizumab, indicating potential for complement blockade.

Cite This Study

Donald et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd03d5783ba022b6fc011 https://doi.org/10.1016/j.kintcr.2026.100049

View Full Paper

Ask AI

Bookmark

Implication

Case report reveals successful treatment of proteinuria in a child with IgA nephropathy using Ravulizumab, indicating potential for complement blockade.

Ravulizumab in Treatment Resistant Paediatric IgA Nephropathy – a Case Report

Key Points

Discussion

Implication

Cite This Study

Ravulizumab in Treatment Resistant Paediatric IgA Nephropathy – a Case Report

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider